<DOC>
	<DOCNO>NCT01692171</DOCNO>
	<brief_summary>The hypothesis trial test drug ( Enoxalow® - T ) pharmacodynamics parameter similar comparator drug ( Clexane® - C ) healthy subject follow administration single intravenous dose . The objective randomized , crossover , clinical trial evaluate pharmacodynamic profile test drug Enoxalow® - T produce Blau Farmacêutica , compare comparator drug Clexane® , produce Sanofi-Aventis , determine pharmacodynamic activity ( include anti FXa anti-FIIa ) , surrogate marker circulate concentration drug .</brief_summary>
	<brief_title>Pharmacodynamics Study Enoxalow Compared Clexane Healthy Subjects After Intravenous Administration</brief_title>
	<detailed_description>In addition pharmacodynamic test Tissue Factor Pathway Inhibitor ( TFPI ) activity , well ratio anti-FXa anti-FIIa activity compare secundary obectives .</detailed_description>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Enoxaparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<criteria>Agree purpose study sign date Informed Consent ; Male , age 18 55 year , clinically healthy ; BMI 18.5 30 ; Participation clinical trial 12 month precede trial ; Presence pulmonary , cardiovascular , neurological , endocrine , gastrointestinal , genitourinary system diseases ; Acute disease period 07 day begin practical phase ( administration drug ) study ; Chronic administration medication hypertension , diabetes disease require continuous use drug ; Hemoglobin &lt; 13 g/dL ; Continuous use oral anticoagulant , platelet inhibitor antiinflammatory drug ; Use medication interact enoxaparin ; History gastrointestinal bleeding , deep vein thrombosis pulmonary embolism may interfere clinical outcome study ; History coagulopathy bleed diathesis ; Presence change physical examination suggestive coagulation disorder ( bruise , petechia , bruise ) ; Body weight &lt; 45 kg &gt; 100 kg ; Absolute platelet count 100 x 109 / L ; History chronic bleeding ; History acute haemorrhage past 30 day ; History sensitivity mammalianderived biological product , albumin component formulation ; History allergy Steven Johnson disease ; Current previous history ( 12 month ) use illicit drug tobacco ; History alcohol abuse , current previous ( within 12 month ) ; At discretion Principal Investigator study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Subjects</keyword>
</DOC>